Cargando…
Torsade de pointes and systemic azole antifungal agents: Analysis of global spontaneous safety reports
Background: Literature about torsade de pointes induced by azole antifungal agents is scarce, despite the well-known association. Furthermore, little is known about the latency time between commencing an azole antifungal agent and developing torsade de pointes. The objectives of the present study we...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Magdi Yacoub Heart Foundation
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5871400/ https://www.ncbi.nlm.nih.gov/pubmed/29644223 http://dx.doi.org/10.21542/gcsp.2017.11 |
_version_ | 1783309642430939136 |
---|---|
author | Salem, M. Reichlin, T. Fasel, D. Leuppi-Taegtmeyer, A. |
author_facet | Salem, M. Reichlin, T. Fasel, D. Leuppi-Taegtmeyer, A. |
author_sort | Salem, M. |
collection | PubMed |
description | Background: Literature about torsade de pointes induced by azole antifungal agents is scarce, despite the well-known association. Furthermore, little is known about the latency time between commencing an azole antifungal agent and developing torsade de pointes. The objectives of the present study were therefore to identify all cases of torsade de pointes associated with systemic azole antifungal use reported to the WHO monitoring centre (Uppsala, Sweden) and to determine the latency times between commencing the azole and developing torsade de pointes. Methods: Investigator-driven, retrospective, descriptive analysis of post-marketing pharmacovigilance data regarding systemic azole antifungal agents and the development of torsade de pointes reported to the WHO monitoring centre 1995–2015. Results: 191 cases were reported as follows: fluconazole 130, itraconazole 22, ketoconazole 5, posaconazole 1, voriconazole 33. More than half of all cases involved concomitant suspected or interacting drugs. The median latency times between starting the azole and developing torsade de pointes ranged from 1 (posaconazole) – 9.5 days (itraconazole), range <1–250). Conclusions: Clinicians should be aware of these features of azole-associated torsade de pointes, avoid interacting drugs if at all possible and monitor at-risk patients. |
format | Online Article Text |
id | pubmed-5871400 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Magdi Yacoub Heart Foundation |
record_format | MEDLINE/PubMed |
spelling | pubmed-58714002018-04-11 Torsade de pointes and systemic azole antifungal agents: Analysis of global spontaneous safety reports Salem, M. Reichlin, T. Fasel, D. Leuppi-Taegtmeyer, A. Glob Cardiol Sci Pract Pharmacovigilance Background: Literature about torsade de pointes induced by azole antifungal agents is scarce, despite the well-known association. Furthermore, little is known about the latency time between commencing an azole antifungal agent and developing torsade de pointes. The objectives of the present study were therefore to identify all cases of torsade de pointes associated with systemic azole antifungal use reported to the WHO monitoring centre (Uppsala, Sweden) and to determine the latency times between commencing the azole and developing torsade de pointes. Methods: Investigator-driven, retrospective, descriptive analysis of post-marketing pharmacovigilance data regarding systemic azole antifungal agents and the development of torsade de pointes reported to the WHO monitoring centre 1995–2015. Results: 191 cases were reported as follows: fluconazole 130, itraconazole 22, ketoconazole 5, posaconazole 1, voriconazole 33. More than half of all cases involved concomitant suspected or interacting drugs. The median latency times between starting the azole and developing torsade de pointes ranged from 1 (posaconazole) – 9.5 days (itraconazole), range <1–250). Conclusions: Clinicians should be aware of these features of azole-associated torsade de pointes, avoid interacting drugs if at all possible and monitor at-risk patients. Magdi Yacoub Heart Foundation 2017-06-30 /pmc/articles/PMC5871400/ /pubmed/29644223 http://dx.doi.org/10.21542/gcsp.2017.11 Text en Copyright © 2017 The Author(s) http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution license CC BY 4.0, which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Pharmacovigilance Salem, M. Reichlin, T. Fasel, D. Leuppi-Taegtmeyer, A. Torsade de pointes and systemic azole antifungal agents: Analysis of global spontaneous safety reports |
title | Torsade de pointes and systemic azole antifungal agents: Analysis of global spontaneous safety reports |
title_full | Torsade de pointes and systemic azole antifungal agents: Analysis of global spontaneous safety reports |
title_fullStr | Torsade de pointes and systemic azole antifungal agents: Analysis of global spontaneous safety reports |
title_full_unstemmed | Torsade de pointes and systemic azole antifungal agents: Analysis of global spontaneous safety reports |
title_short | Torsade de pointes and systemic azole antifungal agents: Analysis of global spontaneous safety reports |
title_sort | torsade de pointes and systemic azole antifungal agents: analysis of global spontaneous safety reports |
topic | Pharmacovigilance |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5871400/ https://www.ncbi.nlm.nih.gov/pubmed/29644223 http://dx.doi.org/10.21542/gcsp.2017.11 |
work_keys_str_mv | AT salemm torsadedepointesandsystemicazoleantifungalagentsanalysisofglobalspontaneoussafetyreports AT reichlint torsadedepointesandsystemicazoleantifungalagentsanalysisofglobalspontaneoussafetyreports AT faseld torsadedepointesandsystemicazoleantifungalagentsanalysisofglobalspontaneoussafetyreports AT leuppitaegtmeyera torsadedepointesandsystemicazoleantifungalagentsanalysisofglobalspontaneoussafetyreports |